An interventional study of Group A (clinical guideline+machine learning) and Group B (clinical guideline+impedance cardiograph+machine learning) in Hypertension, sponsored by China National Center for Cardiovascular Diseases. Completed at 1 site in China. Open to participants aged 35 Years to 79 Years. Per ClinicalTrials.gov, last updated 2026-11-02.
Sponsored by China National Center for Cardiovascular Diseases · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Hypertension by China National Center for Cardiovascular Diseases — 8 open to participants now, 9 under way, none of them phase 3. Hypertension · China National Center for Cardiovascular Diseases.
Among the 17 studies in Hypertension by China National Center for Cardiovascular Diseases, this one is the 5th largest by enrollment of the 16 interventional ones that give a count, is one of 3 that started in 2025, is one of 13 with no phase, and was the 12th registered.
6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.
Browse Hypertension studies →8 of the 17 studies in Hypertension by China National Center for Cardiovascular Diseases are open now, in 1 country. Recruiting first, the newest first:
China National Center for Cardiovascular Diseases · Sites in China
Ages 18+
China National Center for Cardiovascular Diseases · Sites in China
Ages 18+
China National Center for Cardiovascular Diseases · Sites in China
Ages 20–70
China National Center for Cardiovascular Diseases · Sites in China
Ages 18+
China National Center for Cardiovascular Diseases · Sites in China
Ages 40–70 · Healthy volunteers
By country, each count listing its studies:
Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.
This study: 35 Years to 79 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,946 is above the median of 100 across 4,585 interventional studies indexed under Hypertension.
Median enrollment 480 across the 16 interventional studies, 5,000 across the 1 observational. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
China National Center for Cardiovascular Diseases is the lead sponsor of 271 studies on the registry; 143 are open to participants now.
3 of the studies in Hypertension by China National Center for Cardiovascular Diseases that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06055452China National Center for Cardiovascular DiseasesEffects of SGLT2 Inhibitors in Pre-heart Failure Populations With Hypertension | 2026-12-31 |
| NCT05749874China National Center for Cardiovascular DiseasesEffects of Berberine on Preventing Cardiovascular Disease and Diabetes Mellitus | 2026-12-31 |
| NCT07273513China National Center for Cardiovascular Diseases"Smart Family Doctor" Assisted Comprehensive Management of Secondary Prevention Among Post Revascularization Patients | 2026-12-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 17 studies in Hypertension by China National Center for Cardiovascular Diseases, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This trial is a prospective, multicenter, single-blind, three-arm parallel-group, cluster randomized controlled trial assessing the effectiveness and safety of two types of CDSS in primary care settings in China. Primary care sites are randomized to one of the intervention arms or the control arm (1:1:1 ratio) using computer-generated random numbers stratified by region and administrative categories of the primary healthcare institutions (including community health centers, community health stations, and township health centers). A total of 51 primary care sites are randomized to three groups, with 17 sites assigned to group A (use a CDSS based on clinical guidelines and machine learning), 17 sites to group B (use a CDSS based on guidelines, hemodynamic parameters and ML), and the remaining 17 sites to the control group.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Combination Product: Group A (clinical guideline+machine learning)
Combination Product: Group B (clinical guideline+impedance cardiograph+machine learning)
Other: Group C (usual care)
Group A (CG+ML): A Clinical Decision Support System (CDSS) with the algorithm that incorporates clinical guideline (CG) and machine learning (ML) approach.
Group B (CG+ICG+ML): A Clinical Decision Support System (CDSS) with the algorithm that incorporates clinical guideline (CG), hemodynamic parameters measured by impedance cardiograph (ICG), and machine learning (ML) approach.
Control group, the physicians manage the hypertensive patients according to their knowledge and experiences.
hierarchical composite outcome
The primary outcome of the trial is a hierarchical composite outcome, evaluated using the Win-ratio method in the following order: 1. Office blood pressure control (\<130/80 mmHg) at 12 weeks. 2. Time to first blood pressure blood pressure control (\<130/80 mmHg) during study period. 3. The composite index of the number and dosage of antihypertensive drugs.
Time frame: Baseline; 12 weeks.
Individual component of the three-tier hierarchical composite primary outcome at 12 weeks.
Time frame: Baseline; 12 weeks.
Changes in office systolic and diastolic BP from baseline to 4 weeks and 12 weeks.
Time frame: Baseline; 4 weeks, 12 weeks.
Average 24-hour ambulatory systolic and diastolic blood pressure, along with blood pressure control rate at 12 weeks.
Time frame: 12 weeks.
Changes in hemodynamic parameters from baseline to 12 weeks measured by ICG.
Including dynamic parameters (heart rate and cardiac index), resistance parameters (arterial stiffness index and systemic vascular resistance index), and volume parameters (thoracic blood volume saturation)
Time frame: Baseline; 12 weeks.
Differences in the three-tier hierarchical composite primary outcome and each component between the two intervention groups at 12 weeks.
Time frame: Baseline; 12 weeks.
safety outcome
Safety outcomes include serious adverse events, non-serious adverse events, such as symptomatic hypotension or SBP \<90 mmHg, injury falls, syncope, and bradycardia (heart rate \<50 beats/minute) during study periods.
Time frame: Baseline; 12 weeks.
Ran from May 2025 to primary completion in Mar 2026, 9 months.
Of 1,407 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's 9 months is below that.
Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 42.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 2, 2026: primary completion Feb 2026 → Mar 2026 and completion May 2026 → Mar 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
China National Center for Cardiovascular Diseases →